Sarcoma 
Welcome,         Profile    Billing    Logout  

521 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarcoma
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29
SC9/ABX, NCT04528680: Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma

Recruiting
1/2
57
US
Sonication for opening of blood-brain barrier, SonoCloud-9 device, SC-9, Chemotherapy, albumin-bound paclitaxel, Abraxane®, ABX, Chemotherapy, carboplatin, Paraplatin
Northwestern University, CarThera, Bristol-Myers Squibb, Lantheus Medical Imaging
Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Recurrent Glioblastoma
09/24
09/25
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1/2
50
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

Recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
12/24
12/24
CA209-9WW, NCT03628209: Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Active, not recruiting
1/2
21
US
Nivolumab, Opdivo®, Azacitidine, Vidaza®, Post Treatment Surgery, Standard of Care, Resection of disease
H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma Recurrent, Sarcoma
12/24
12/24
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/24
03/27
TRuST, NCT02875548 / 2015-004984-35: A Study to Assess the Long-term Safety of Tazemetostat

Enrolling by invitation
1/2
100
Europe, US, RoW
Tazemetostat, EPZ-6438, E7438, IPN60200
Epizyme, Inc.
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epitheliod Sarcoma (ES), Mesothelioma, Advanced Solid Tumors, Renal Medullary Carcinoma, Non-Hodgkin Lymphoma (NHL)
11/25
11/25
REGOMUNE, NCT03475953: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Recruiting
1/2
747
Europe
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib
Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
12/24
12/25
AMPHISARC, NCT05180695: HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas

Recruiting
1/2
58
Europe
Pazopanib, Votrient, HDM201, siremadlin
Centre Leon Berard, Novartis, National Cancer Institute, France
Advanced Soft-tissue Sarcoma, Metastatic Soft-tissue Sarcoma
01/26
07/26
NCT05301764: A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma

Recruiting
1/2
65
RoW
LVGN6051 and Anlotinib
Lyvgen Biopharma Holdings Limited
Soft Tissue Sarcoma
03/25
10/25
NCT05275478: Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
192
Europe, US
TNG908
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
04/25
09/25
KEYNOTE-E37, NCT04725331: A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors

Recruiting
1/2
48
Europe
BT-001, Pembrolizumab [KEYTRUDA®], KEYTRUDA®
Transgene, BioInvent International AB, Merck Sharp & Dohme LLC
Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Non Small Cell Lung Cancer
04/25
04/25
NCT05944224: A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting
1/2
63
RoW
SPH4336, Cadonilimab
Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumors
05/25
12/25
SAKK 66/17, NCT03993678: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

Recruiting
1/2
39
Europe
IP-001, Thermal Ablation, TRANBERG Thermal Therapy System®, Thermal Therapy System (Clinical Laserthermia Systems AB)
Swiss Group for Clinical Cancer Research, Immunophotonics, Inc.
Advanced Solid Tumors
06/25
12/25
NCT05588648: Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma

Recruiting
1/2
48
US, RoW
Vactosertib, TEW-7197
MedPacto, Inc.
Osteosarcoma
07/25
11/25
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
67
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/25
09/25
KEYNOTE-B59, NCT04977453: GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors

Recruiting
1/2
430
US, RoW
GI-101, Pembrolizumab (KEYTRUDA®), KEYTRUDA®, Lenvatinib, Lenvima®, Local Radiotherapy, GI-101A
GI Innovation, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Renal Cell Carcinoma, Urinary Bladder Cancer, Melanoma, Sarcoma, Microsatellite Stable Colorectal Carcinoma, Merkel Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Vaginal Cancer, Vulvar Cancer
10/25
10/26
VELA, NCT05252416: () Study of BLU-222 in Advanced Solid Tumors

Hourglass Jan 2023 - Jun 2023 : Initial clinical data from VELA trial in CDK2-vulnerable cancers
Hourglass Jan 2023 - Jun 2023 : Anticipated results from VELA study for BLU-222 in CDK2-vulnerable cancers
Hourglass Jun 2023 - Jun 2023 : Safety and efficacy data from VELA trial in breast cancer and other cancers vulnerable to CDK2 inhibition
Recruiting
1/2
366
Europe, US
BLU-222, Carboplatin, Ribociclib, Fulvestrant
Blueprint Medicines Corporation
Advanced Solid Tumors, HR+ Breast Cancer, CCNE1 Amplification, HER2-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Carcinosarcoma
11/25
09/26
NCT05266196: A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Enrolling by invitation
1/2
10
US
Seclidemstat, topotecan, cyclophosphamide
Salarius Pharmaceuticals, LLC
Ewing Sarcoma, Myxoid Liposarcoma, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Myoepithelial Tumor, Low Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma
12/25
12/25
NCT05902988: A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Recruiting
1/2
120
US
VLS-1488
Volastra Therapeutics, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
12/25
06/26
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT05955105: A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Recruiting
1/2
200
RoW
ILB-2109, Toripalimab
Innolake Biopharm
Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Melanoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Classic Hodgkin Lymphoma
01/26
07/26
NCT05652855: Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors

Not yet recruiting
1/2
48
RoW
MHB088C for Injection
Minghui Pharmaceutical Pty Ltd
Advanced or Metastatic Solid Tumors
01/26
07/26
NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
159
Europe, US
TNG462
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
NCT04557449: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

Recruiting
1/2
337
Europe, Japan, US, RoW
PF-07220060, Letrozole, Femara, Fulvestrant, Faslodex, Midazolam, Enzalutamide, Xtandi
Pfizer
Liposarcoma, CRC, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung, Solid Tumors
03/27
05/28
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
NCT06090266: A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

Recruiting
1/2
168
US
OR502, Cemiplimab
OncoResponse, Inc.
Cancer, Tumor, Solid, Malignant Neoplasm, Metastatic Cancer, Advanced Solid Tumor, Platinum-resistant Ovarian Cancer, Cutaneous Squamous Cell Carcinoma
08/26
02/27
NCT05944237: HTL0039732 in Participants With Advanced Solid Tumours

Recruiting
1/2
150
Europe
HTL0039732 Capsules, HTL0039732 Capsules and atezolizumab infusion
Cancer Research UK, Heptares Therapeutics Limited
Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Colorectal Neoplasms, Pancreatic Neoplasms, Lung Neoplasms, Urinary Bladder Neoplasms, Mesothelioma, Malignant, Uterine Cervical Neoplasms, Kidney Neoplasms, Sarcoma, Pheochromocytomas
09/26
09/26
NCT05642455: SPEARHEAD-3 Pediatric Study

Recruiting
1/2
20
US
Afamitresgene autoleucel
Adaptimmune
Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST), Neuroblastoma, Osteosarcoma
10/26
07/38
AMPLIFY-7P, NCT05726864: A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Recruiting
1/2
156
US
ELI-002 7P
Elicio Therapeutics
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, KRAS G12D, KRAS G12R, KRAS G12V, KRAS G12A, KRAS G12C, KRAS G12S, KRAS G13D, NRAS G12D, NRAS G12R, NRAS G12V, NRAS G12C, NRAS G12S
11/26
11/26
EMERGE 101, NCT05734066: Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Recruiting
1/2
60
Canada, US
Lurbinectedin, JZP712
Jazz Pharmaceuticals
Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma, Ewing Sarcoma
12/26
06/27
NCT03465592: Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma

Recruiting
1/2
39
US
Nivolumab, BMS-936558, MDX1106, ONO-4538
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bristol-Myers Squibb
Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood
01/27
03/29
TAZNI, NCT05407441: Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors

Recruiting
1/2
49
US
Tazemetostat, TAZVERIK, Nivolumab, OPDIVO, Ipilimumab, YERVOY
Susan Chi, MD, Bristol-Myers Squibb, Epizyme, Inc.
Atypical Teratoid Rhabdoid Tumor, INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors, SMARCA4-deficient Primary CNS Malignant Tumors, Malignant Rhabdoid Tumor (MRT), Rhabdoid Tumor of the Kidney (RTK), Epithelioid Sarcoma, Chordoma
02/27
02/29
NCT05957367: A Study of DCC-3116 in Combination With Anticancer Therapies in Participants With Advanced Malignancies

Recruiting
1/2
94
US
DCC-3116, Ripretinib, QINLOCK, DCC-2618
Deciphera Pharmaceuticals LLC, Pfizer
GIST
03/27
06/27
NCT05864144: A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Recruiting
1/2
169
US
SNS-101 (anti-VISTA), Cemiplimab
Sensei Biotherapeutics, Inc., Regeneron Pharmaceuticals
Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
06/27
06/27
NCT06024174: A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors

Terminated
1/2
5
Europe, US, RoW
BMS-986466, BBP-398, IACS-15509, Adagrasib, MRTX849, KRAZATI®, Cetuximab, Erbitux®
Bristol-Myers Squibb
Advanced Solid Tumors
05/24
05/24
NEXIS, NCT03116529: Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

Active, not recruiting
1/2
22
US
Combination Radiation, Immunotherapy, Surgery
University of Maryland, Baltimore, AstraZeneca, University of Arizona, West Penn Allegheny Health System
Soft Tissue Sarcoma
06/32
06/37
KEYNOTE-505, NCT03126591: A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Completed
1a/1b
38
Europe, US
Olaratumab, LY3012207, Pembrolizumab, MK3475
Eli Lilly and Company, Merck Sharp & Dohme LLC
Soft Tissue Sarcoma
05/21
02/23
TQB2858-Ib-02, CTR20220390: Single-arm, open-label, multi-center phase Ib clinical trial of TQB2858 injection for the treatment of advanced high-grade sarcoma

Active, not recruiting
1b
100
China
TQB2858 - Sino Biopharm
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd
Advanced high-grade sarcoma
 
 
TQB2450-Ib-02, CTR20190938: TQB2450 clinical study in combination with anlotinib in the treatment of soft tissue sarcoma

Ongoing
1b
30
China
benmelstobart (APL-502) - Apollomics, Focus V (anlotinib) - Advenchen, Sino Biopharm
Nanjing Shunxin Pharmaceutical Co., Ltd./ Chia Tai Tianqing Pharmaceutical Group Co., Ltd
Advanced soft tissue sarcoma
 
 
NCT03009201: Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Completed
1b
16
US
Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib, Kisqali, LEE-011, LEE011
OHSU Knight Cancer Institute, Novartis Pharmaceuticals, Oregon Health and Science University
Advanced Soft Tissue Sarcoma, Locally Advanced Angiosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Malignant Peripheral Nerve Sheath Tumor, Locally Advanced Myxofibrosarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Epithelioid Sarcoma, Metastatic Fibrosarcoma, Metastatic Liposarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Myxofibrosarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma, Pleomorphic Rhabdomyosarcoma, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Undifferentiated (Embryonal) Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Soft Tissue Sarcoma, Unresectable Synovial Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
10/19
06/23
OV2-RRST-101, NCT05361954: Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors

Not yet recruiting
1b
36
NA
STI-1386, Seprehvec
Sorrento Therapeutics, Inc.
Cancer, Cancer of Pancreas, Sarcoma, Hepatic Metastasis, Solid Tumor
10/26
02/27
NCT02369185: Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Not yet recruiting
1
21
US
BLZ-100, Tumor Paint
Blaze Bioscience Inc., National Cancer Institute (NCI)
Sarcoma, Soft Tissue
06/16
09/16
NCT01638533: Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Active, not recruiting
1
37
Canada, US
Pharmacological Study, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic
National Cancer Institute (NCI), Celgene Corporation
Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm, Neuroendocrine Neoplasm, Recurrent Adult Soft Tissue Sarcoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Colorectal Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Lung Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Pancreatic Carcinoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Prostate Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Breast Cancer AJCC v7, Stage III Colorectal Cancer AJCC v7, Stage III Cutaneous Melanoma AJCC v7, Stage III Lung Cancer AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage III Prostate Cancer AJCC v7, Stage III Renal Cell Cancer AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Colorectal Cancer AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Colorectal Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IIIC Colorectal Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Colorectal Cancer AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Lung Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7, Unresectable Solid Neoplasm
11/18
03/25
NCT05800106: A Bioequivalence Study of Sunitinib Malate Capsules.

Completed
1
24
RoW
Sunitinib malate capsules generic product, Sunitinib malate capsules reference product
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gastrointestinal Stromal Tumors, Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumor
01/19
01/19
NCT00089245 / 2020-001590-68: Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer

Terminated
1
177
US
Iodine I 131 MOAB 8H9
Y-mAbs Therapeutics, Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
02/22
02/22
CTR20192611: Phase I clinical study of TAEST16001 injection in patients with solid tumors

Completed
1
18
China
TAEST16001 - Guangzhou Xiangxue Pharma, Athenex
Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Advanced malignant solid tumors, mainly soft tissue sarcomas
 
 
TRAMUNE, NCT03085225: Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.

Checkmark From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Sep 2020 - Sep 2020: From TRAMUNE trial in combination with trabectedin in locally advanced/unresectable soft-tissue sarcoma at ESMO 2020
Completed
1
40
Europe
Combination of trabectedin with durvalumab
Institut Bergonié, AstraZeneca, PharmaMar
Ovarian Carcinoma, Soft Tissue Sarcoma
11/20
01/22
OU-SCC-EXIST-001, NCT03206177: Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

Active, not recruiting
1
26
US
Galunisertib, Paclitaxel, Carboplatin
University of Oklahoma, Eli Lilly and Company
Carcinosarcoma, Ovarian
07/21
08/23
NCT02386826: INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme

Completed
1
65
US
INC280, INCB28060, bevacizumab, Avastin
SCRI Development Innovations, LLC, Novartis
Glioblastoma Multiforme, Gliosarcoma, Colorectal Cancer, Renal Cell Carcinoma
07/21
08/23
NCT02897375: Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Completed
1
71
US
Carboplatin, Paraplatin, Cisplatin, CDDP, Cis-diamminedichloridoplatinum, Cisplatinum, Cismaplat, Neoplatin, Palbociclib, Ibrance, PD-0332991
Emory University, Pfizer, National Institutes of Health (NIH), National Cancer Institute (NCI)
Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Sarcoma, Colorectal Cancer, Head and Neck Cancer, Cancer of Unknown Primary, Bladder Cancer, Ovarian Cancer
10/21
10/21
NCT03043391: Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children

Completed
1
8
US
Polio/Rhinovirus Recombinant (PVSRIPO)
Istari Oncology, Inc., Solving Kids' Cancer, The Andrew McDonough B+ Foundation, Duke University
Malignant Glioma, Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Glioblastoma, Gliosarcoma, Atypical Teratoid/Rhabdoid Tumor of Brain, Medulloblastoma, Ependymoma, Pleomorphic Xanthoastrocytoma of Brain, Embryonal Tumor of Brain
03/22
03/22
2021-001488-25: A clinical trial to look at the safety and potential efficacy of FHD-609 in people with advanced synovial sarcoma Un ensayo clínico para estudiar la seguridad y la posible eficacia de FHD-609 en personas con sarcoma sinovial avanzado

Not yet recruiting
1
70
Europe
-, FHD-609, Lyophilisate for solution for infusion
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma (SS) Sarcoma Sinovial (SS) Avanzado, Synovial Sarcoma (SS) Sarcoma Sinovial (SS), Diseases [C] - Cancer [C04]
 
 
NCT04318964: TAEST16001 in the Treatment of Soft Tissue Sarcoma

Active, not recruiting
1
12
RoW
TAEST16001 cells
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
04/22
05/24
NCT02658981: Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Completed
1
63
US
Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, BMS-936558, Nivolumab, Pharmacological Study, Laboratory Biomarker Analysis, Anti-CD137, urelumab
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, National Cancer Institute (NCI), Bristol-Myers Squibb
Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
04/22
10/23
NCT04864821: Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor

Not yet recruiting
1
24
NA
Targeting CD276 CAR T cells
PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University
Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
05/22
05/23
NCT04900766: A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Terminated
1
31
RoW
Mitoxantrone Hydrochloride Liposome Injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Unresectable or Metastatic Bone and Soft Tissue Sarcoma
02/23
02/23
NCT06413095: PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

Completed
1
13
US
Pembrolizumab, Keytruda, MK-3475, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Presage Biosciences, Merck Sharp & Dohme LLC
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
06/23
06/23
NCI-2018-00438, NCT03552471: Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Active, not recruiting
1
25
US
Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, IMGN853, M9346A-sulfo-SPDB-DM4, Pharmacokinetic Study, PHARMACOKINETIC, PK Study, Rucaparib Camsylate, 8-Fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonic Acid Salt, C0-338, Rubraca, Rucaparib Phosphate
Ohio State University Comprehensive Cancer Center, ImmunoGen, Inc., Clovis Oncology, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Uterine Serous Carcinoma, Recurrent Uterine Carcinosarcoma, Platinum Resistant Ovarian Cancer
06/22
12/23
NCT03960060: A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

Active, not recruiting
1
18
RoW
CCT301-59
Shanghai PerHum Therapeutics Co., Ltd., Shanghai Zhongshan Hospital
Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer
06/22
06/23
NCT04714983: DNX-2440 for Resectable Colorectal Liver Metastasis

Suspended
1
30
US
DNX-2440
DNAtrix, Inc., H. Lee Moffitt Cancer Center and Research Institute
Liver Metastases, Liver Metastasis Colon Cancer, Colorectal Cancer, Breast Cancer, Gastric Cancer, Periampullary Cancer, Melanoma, Renal Cell Cancer, Sarcoma, Squamous Cell Carcinoma, Gastrointestinal Stromal Tumors
07/26
12/26
NCT03829436: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

Completed
1
38
US
Part 1 TPST-1120, Experimental, Part 2 TPST-1120 + nivolumab, Experimental + Opdivo, Part 3 TPST-1120, Part 4 TPST-1120 + nivolumab
Tempest Therapeutics
Hepatocellular Carcinoma, Metastatic Castration Resistant Prostate Cancer, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma of Head and Neck, Triple-Negative Breast Cancer, Urothelial Carcinoma, Cholangiocarcinoma, GastroEsophageal Cancer, Pancreatic Cancer, Sarcoma
09/22
09/22
TQB2858-Ⅰ-05, CTR20213001: Phase I clinical trial to evaluate the tolerability and pharmacokinetics of TQB2858 injection in subjects with advanced malignant tumors

Terminated
1
163
China
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Alveolar soft tissue sarcoma
 
 
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
09/22
12/24
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
NCT05061537: Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Terminated
1
13
US
PF-07263689, Sasanlimab
Pfizer
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
10/22
10/22
NCT05943990: Study of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Terminated
1
5
Europe, Canada, US, RoW
GSK3845097, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
10/22
10/22
AMPLIFY-201, NCT04853017: A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Active, not recruiting
1
25
US
ELI-002 2P
Elicio Therapeutics
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
01/23
03/26
NCT04837677: A Study of PRT1419 in Patients With Advanced Solid Tumors

Completed
1
26
US
PRT1419
Prelude Therapeutics
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
02/23
02/23
NCT03361436: Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Active, not recruiting
1
15
US
Eribulin Mesylate, B1939 Mesylate, E7389, ER-086526, Halaven, Halichondrin B Analog, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Therapeutic Conventional Surgery
OHSU Knight Cancer Institute, Eisai Inc., Oregon Health and Science University
Liposarcoma, Malignant Abdominal Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Scrotal Neoplasm, Malignant Solid Neoplasm, Malignant Spermatic Cord Neoplasm
02/23
04/33
NCT02736565: Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma

Completed
1
7
US
pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex, Lipoplex
Gradalis, Inc.
Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma
08/19
08/20
NCI-2018-00615, NCT03670069: Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Terminated
1
27
US
Itacitinib, 1334298-90-6, 3-Azetidineacetonitrile, INCB039110, Laboratory Biomarker Analysis
Fred Hutchinson Cancer Center, Incyte Corporation
Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Refractory Leiomyosarcoma, Refractory Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Soft Tissue Sarcoma, Refractory Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Advanced Synovial Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Chondrosarcoma
03/23
05/24
NCT04537715: Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Completed
1
42
Europe, US
Tazemetostat, EPZ-6438, Tazverik, Itraconazole, Sporanox, Rifampin, RIF, Rifampicin, Rifadin, Rimactane
Epizyme, Inc.
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
04/23
04/23
GEN-602-CT-101, NCT03775525: Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Active, not recruiting
1
127
US
GZ17-6.02, Capecitabine, Xeloda
Genzada Pharmaceuticals USA, Inc., Translational Drug Development
Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach, Lymphoma, Sarcoma, Cutaneous T Cell Lymphoma, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Cutaneous T-cell Lymphoma, Cutaneous Squamous Cell Carcinoma
05/23
12/23
NCT05100628: A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

Terminated
1
10
US
NOX66, Doxorubicin
Noxopharm Limited
Metastatic Soft-tissue Sarcoma
05/23
05/23
NCT02962167: Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

Completed
1
34
US
Modified Measles Virus, MV-NIS, Modified Measles Virus Lumbar Puncture, MV-NIS LP
Sabine Mueller, MD, PhD, No More Kids With Cancer, The Matthew Larson Foundation for Pediatric Brain Tumors, Vyriad, Inc., Mayo Clinic
Medulloblastoma, Childhood, Recurrent, Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent
05/23
05/23
NCT04052334: Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma

Completed
1
9
US
TIL, Tumor-infiltrating lymphocytes, Interleukin-2, IL-2, Fludarabine, Fludara, Cyclophosphamide, Cytoxan, Neosar
H. Lee Moffitt Cancer Center and Research Institute, Iovance Biotherapeutics, Inc., The V Foundation for Cancer Research, National Cancer Institute (NCI)
Sarcoma
05/23
05/24
NCT06048705: Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

Terminated
1
7
Europe, Canada, US, RoW
GSK3901961, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
06/23
06/23
ALS-6000-101, NCT04969835: A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Recruiting
1
80
Europe, US
AVA6000
Avacta Life Sciences Ltd
Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Cancer of Unknown Primary Site, Ovarian Cancer, Breast Cancer, Soft Tissue Sarcoma, Bladder Cancer, Oesophageal Cancer, Prostate Cancer, Biliary Tract Cancer
05/23
06/23
NCT05043649: Camsirubicin + Pegfilgrastim to Determine MTD in ASTS

Terminated
1
14
US
Camsirubicin
Monopar Therapeutics
Advanced Soft-tissue Sarcoma
10/23
05/24
NCT06171282: A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Recruiting
1
9
RoW
Recombinant oncolytic herpes simplex virus type Ⅰ (R130), Oncolytic virus Injection
Shanghai Yunying Medical Technology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Osteosarcoma, Sarcoma, Soft Tissue Sarcoma, Bone Tumor
07/25
07/26
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT04556669: Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors

Recruiting
1
30
RoW
Autologous aPD-L1 armored anti-CD22 CAR T cells
Hebei Senlang Biotechnology Inc., Ltd.
Solid Tumor, Adult, Cervical Cancer, Sarcoma, NSCLC
08/23
08/25
NCT02869217: Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors

Checkmark From P1 trial at ESMO 2019 [screenshot]
Sep 2019 - Sep 2019: From P1 trial at ESMO 2019 [screenshot]
Checkmark Data presentation from P1 trial in solid tumors
Jun 2019 - Jun 2019: Data presentation from P1 trial in solid tumors
Hourglass Nov 2016 - Mar 2017 : Initiation of trial in synovial sarcoma
Active, not recruiting
1
22
Canada
Cyclophosphamide, TBI-1301, Fludarabine
University Health Network, Toronto, Takara Bio Inc.
NY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive Patients, Synovial Sarcoma, Melanoma, Esophageal Cancer, Ovarian Cancer, Lung Cancer, Bladder Cancer, Liver Cancer
09/24
09/24
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
NCT03896568: MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recruiting
1
36
US
Oncolytic Adenovirus Ad5-DNX-2401, Ad5-Delta24RGD, DNX-2401, DNX2401, Oncolytic Ad5-Delta 24RGD, Oncolytic Adenovirus Ad5-Delta 24RGD, Therapeutic Conventional Surgery
M.D. Anderson Cancer Center, DNAtrix, Inc.
IDH1 wt Allele, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Malignant Glioma
09/27
09/27
NCT05159518: A Study of PRT2527 in Participants With Advanced Solid Tumors

Completed
1
30
US
PRT2527
Prelude Therapeutics
Sarcoma, Castrate Resistant Prostate Cancer, Hormone Receptor Positive HER2 Negative Breast Cancer, Non-small Cell Lung Cancer, Solid Tumors With Known MYC Amplification
12/23
12/23
NCT05492682: START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

Recruiting
1
15
Europe
PeptiCRAd-1, Cyclophosphamide, Pembrolizumab
Valo Therapeutics Oy
Melanoma (Skin), Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Synovial Sarcoma, Myxoid Liposarcoma, Colorectal Cancer
06/25
09/25
NCT06156410: Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Recruiting
1
30
US
Cabozantinib
Children's Hospital of Philadelphia, Children's Hospital Colorado, Exelixis, Alex's Lemonade Stand Foundation
Ewing Sarcoma, Osteosarcoma
11/27
11/28
NCT04908176: A Drug-drug Interaction Study of Avapritinib and Midazolam

Active, not recruiting
1
10
US
Avapritinib, BLU-285, midazolam
Blueprint Medicines Corporation
Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
03/24
09/25
NCT03454451: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Completed
1
117
US, RoW
CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
Corvus Pharmaceuticals, Inc.
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma
12/22
02/23
NCT04149691: Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies

Recruiting
1
42
Europe
CPL304110, PG19
Celon Pharma SA, National Center for Research and Development, Poland
Gastric Cancer, Bladder Cancer, Squamous Non-small Cell Lung Cancer, Cholangiocarcinoma, Sarcoma, Endometrial Cancer, Other Solid Tumours
06/24
06/24
DOXO75, NCT04032964: Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

Active, not recruiting
1
2
US
L19TNF, DOXORUBICIN
Philogen S.p.A.
Soft Tissue Sarcoma
12/24
12/24
NCT05578820: Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Recruiting
1
12
RoW
Intratumoral administration of Stimotimagene copolymerplasmid, Intravenous administration of Ganciclovir (Cymeven®)
Gene Surgery LLC
Sarcoma, Melanoma, Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Uterine Cervical Neoplasms, Vulvar Neoplasms, Penile Neoplasms, Anus Neoplasms
12/23
12/23
FRONTIER, NCT05432193: FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors

Active, not recruiting
1
10
Canada, US
[Ga-68]-PNT6555, [Lu-177]-PNT6555
POINT Biopharma
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin), Soft Tissue Sarcoma, Head and Neck Squamous Cell Carcinoma, Cholangiocarcinoma
12/23
12/26
CEB-01-RLS01-CT, NCT04619056: First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma

Active, not recruiting
1
21
Europe
CEB-01 membrane loaded with SN-38
CEBIOTEX
Locally Advanced Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma
05/25
05/25
NCT04000529: Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Terminated
1
122
Europe, Japan, US, RoW
TNO155, Spartalizumab, PDR001, Ribociclib, LEE011
Novartis Pharmaceuticals
Non-small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, Esophageal SCC, Gastrointestinal Stromal Tumors, Colorectal Cancer
01/24
01/24
DIPG, NCT04341311: Phase I Study of Marizomib + Panobinostat for Children With

Terminated
1
4
US
Marizomib, salinosporamide A, salinosporin A, Panobinostat, Farydak
Dana-Farber Cancer Institute, Celgene, Secura Bio, Inc.
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
02/24
02/24
HFB-301001-01, NCT05229601: A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

Active, not recruiting
1
84
Europe, US
HFB301001
HiFiBiO Therapeutics
Soft Tissue Sarcoma, Renal Cell Carcinoma, Uterine Carcinosarcoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma
01/25
01/25
 

Download Options